Nutritional supplements that contain curcumin -- a natural anti-inflammatory compound -- may protect the eyes from the ...

The therapy, called photobiomodulation or “red light” therapy, can reduce the risk of vision loss and slow progression of the ...

Light therapy could be a useful treatment for the most common form of age-related macular degeneration ... drugs available for people with "wet" AMD, in which leaking blood vessels damage the ...

Dr. Shiri Shulman from Assuta discusses the importance of continuity in treatment during wartime and innovative therapies ...

There are various factors that may potentially increase the risk of developing AMD, such as advancing age (over 50); having a ...

Dr Arshad Khanani anticipates presentations offering new strategies to tackle challenges such as macular atrophy and fibrosis, and optimizing dosing intervals in wet AMD.

While adverse events (AEs) were reported for 97% of trial participants, such cases were predominantly mild to moderate.

Data about higher doses that are injected less often come as the original 2-milligram dose of Eylea is facing an increasing ...

Pharmaceuticals announced that the first patient has been dosed in the Phase 3 LUGANO clinical trial of DURAVYU, formerly ...

ROCKVILLE, Md. - REGENXBIO Inc. (NASDAQ:RGNX) has reported significant advancements in the treatment of wet age-related macular degeneration (wet AMD (NASDAQ:AMD)), a common retinal disease.

Regenxbio and AbbVie announced positive Phase II results for gene therapy ABBV-RGX-314 in wet AMD, showing a 97% reduction in ...